<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105074</url>
  </required_header>
  <id_info>
    <org_study_id>18-0116-A</org_study_id>
    <nct_id>NCT05105074</nct_id>
  </id_info>
  <brief_title>Does the Use of Intrathecal Morphine Increase the Length of Hospital Stay in Fast Track Orthopedic Procedures?</brief_title>
  <official_title>Does the Use of Intrathecal Morphine Increase the Length of Hospital Stay in Fast Track Orthopedic Procedures?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial of intrathecal morphine for patients Patient with primary as well as&#xD;
      revision knee and hip arthroplasty under regional anesthesia. This study would include a&#xD;
      total of 134 patients. It is the intention to randomize these patients postoperatively into 2&#xD;
      groups of patients:&#xD;
&#xD;
      Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose&#xD;
      of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.&#xD;
&#xD;
      Group 2 - Patients will not receive intrathecal morphine. Patients will receive only&#xD;
      bupivacaine and 15 mcg of fentanyl for spinal anesthesia.&#xD;
&#xD;
      It is postulated that the use of intrathecal morphine may be associated with an increase&#xD;
      length of stay in the hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedures:&#xD;
&#xD;
      Preoperative phase- The patients will receive the consent form together with the standard&#xD;
      sheet in the pre-admission unit or remotely via telephone or email, usually one week before&#xD;
      surgery, explaining intrathecal morphine and its benefits and drawbacks. These patients will&#xD;
      receive an educational booklet regarding the &quot;fast track protocol&quot; which includes clear&#xD;
      instruction related to their upcoming surgery. The material covers a wide range of topics&#xD;
      such as instructions related to fasting for solids and liquids before coming for surgery, the&#xD;
      expectation of pain relief and physiotherapy, types of anesthesia and expected length of&#xD;
      hospital stay. Upon hospital admission, one hour before the procedure, patients will receive&#xD;
      gabapentin 300mg, celecoxib 400mg (will be reduced to celecoxib 200mg in patients â‰¥ 65 years&#xD;
      old) and acetaminophen 1000mg orally.&#xD;
&#xD;
      Intraoperative phase- Surgical procedures to be included in the study are elective primary as&#xD;
      well as revision arthroplasty of knee and hip joints under spinal anesthesia with or without&#xD;
      sedation. Patient will be randomized to one of two groups. One group will receive intrathecal&#xD;
      morphine 100 mcg in addition to the standard dose of bupivacaine and fentanyl 15 mcg for&#xD;
      spinal anesthesia and another group will not receive intrathecal morphine. Upon prosthesis&#xD;
      implant, the surgeon will infiltrate periarticular 100 ml (40 ml bupivacaine 0.5% + 60 ml of&#xD;
      normal saline) as per the orthopedic protocol. Sedation will be titrated to keeping modified&#xD;
      Ramsay sedations score (RSS) between 3 and 5.&#xD;
&#xD;
      Postoperative phase- upon emergence from anesthesia patients will be taken to the recovery&#xD;
      room. As per our hospital protocol, the patient will be catheterized if the bladder residual&#xD;
      volume by ultrasound is 500ml or more. Post-operative pain score and opioid requirements and&#xD;
      complications including urinary retention, vomiting and respiratory depression will be&#xD;
      recorded. Overall duration of stay in the hospital will be noted. If any patient requires&#xD;
      catheterization of bladder, the duration of catheter requirement and frequency of&#xD;
      catheterization will be monitored and recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>From admission to the hospital until discharge, an average of 3 days</time_frame>
    <description>Duration of stay in the hospital in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of opioid related side effects</measure>
    <time_frame>48 Hours post operatively</time_frame>
    <description>Nausea, Vomiting, Constipation, Difficulty passing urine, Difficulty concentrating, Dizziness, Drowsiness, Feeling confused, Fatigue, Itchiness, Dry mouth, Headache.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Spinal Anesthesia to bladder catheterization</measure>
    <time_frame>During the hospital admission, an average of 3 days</time_frame>
    <description>Time from Spinal Anesthesia to bladder catheterization (Foley catheterization or In and Out catheterization ) in hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores measured at rest and movement twice a day</measure>
    <time_frame>48 Hours post operatively</time_frame>
    <description>Based on Verbal Analogue Scale (VAS) scoring system (0-10), where score of 0 refers to no pain and a score of 10 refers to the worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall feeling/ satisfaction about pain treatment</measure>
    <time_frame>At the time of discharge from hospital, an average of 3 days</time_frame>
    <description>Patient satisfaction from pain management during hospital stay, from score of 1(very dissatisfied) to score of 6 (Very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Arthropathy of Knee</condition>
  <condition>Arthropathy of Hip</condition>
  <arm_group>
    <arm_group_label>Intrathecal Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One group will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and fentanyl 15 mcg for spinal anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One group will receive normal saline 100 mcg in addition to the standard dose of bupivacaine and fentanyl 15 mcg for spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal Morphine</intervention_name>
    <description>Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.</description>
    <arm_group_label>Intrathecal Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA 1-3&#xD;
&#xD;
          -  Age 18 to 85 years&#xD;
&#xD;
          -  BMI 18 to 40 kg/cm2&#xD;
&#xD;
          -  Patient with primary as well as revision knee and hip arthroplasty under regional&#xD;
             anesthesia only.&#xD;
&#xD;
          -  Provision of written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Language barrier or difficulty in communication: inability to read write or speak&#xD;
             English&#xD;
&#xD;
          -  Allergy to morphine&#xD;
&#xD;
          -  Patients under increased risk for respiratory depression with intrathecal morphine&#xD;
             (central apnea)&#xD;
&#xD;
          -  Patients with pre-existing urinary problems&#xD;
&#xD;
          -  Women of child bearing potential not on birth control&#xD;
&#xD;
          -  Patients with chronic pain who are currently on pain medications&#xD;
&#xD;
          -  Patients with cognitive impairment&#xD;
&#xD;
          -  Patients who have alcohol and/or other substance dependency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Naveed Siddiqui, MD</last_name>
    <phone>: 416-586-4800</phone>
    <phone_ext>5270</phone_ext>
    <email>naveed.siddiqui@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveed Siddiqui, MD</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>5270</phone_ext>
      <email>naveed.siddiqui@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Naveed Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yehoshua Josh Gleicher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammad Imran Khan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Backstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashok Kumar Jayaraj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yusuke Mazda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Teresi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Petros JG, Rimm EB, Robillard RJ. Factors influencing urinary tract retention after elective open cholecystectomy. Surg Gynecol Obstet. 1992 Jun;174(6):497-500.</citation>
    <PMID>1350689</PMID>
  </reference>
  <reference>
    <citation>Huang A, Ryu JJ, Dervin G. Cost savings of outpatient versus standard inpatient total knee arthroplasty. Can J Surg. 2017 Feb;60(1):57-62.</citation>
    <PMID>28234591</PMID>
  </reference>
  <reference>
    <citation>Murphy PM, Stack D, Kinirons B, Laffey JG. Optimizing the dose of intrathecal morphine in older patients undergoing hip arthroplasty. Anesth Analg. 2003 Dec;97(6):1709-1715. doi: 10.1213/01.ANE.0000089965.75585.0D.</citation>
    <PMID>14633547</PMID>
  </reference>
  <reference>
    <citation>David M, Arthur E, Dhuck R, Hemmings E, Dunlop D. High rates of postoperative urinary retention following primary total hip replacement performed under combined general and spinal anaesthesia with intrathecal opiate. J Orthop. 2015 Nov 18;12(Suppl 2):S157-60. doi: 10.1016/j.jor.2015.10.020. eCollection 2015 Dec.</citation>
    <PMID>27047216</PMID>
  </reference>
  <reference>
    <citation>Min BW, Kim Y, Cho HM, Park KS, Yoon PW, Nho JH, Kim SM, Lee KJ, Moon KH. Perioperative Pain Management in Total Hip Arthroplasty: Korean Hip Society Guidelines. Hip Pelvis. 2016 Mar;28(1):15-23. doi: 10.5371/hp.2016.28.1.15. Epub 2016 Mar 31. Review.</citation>
    <PMID>27536639</PMID>
  </reference>
  <reference>
    <citation>McCartney CJ, McLeod GA. Local infiltration analgesia for total knee arthroplasty. Br J Anaesth. 2011 Oct;107(4):487-9. doi: 10.1093/bja/aer255.</citation>
    <PMID>21903643</PMID>
  </reference>
  <reference>
    <citation>Jia XF, Ji Y, Huang GP, Zhou Y, Long M. Comparison of intrathecal and local infiltration analgesia by morphine for pain management in total knee and hip arthroplasty: A meta-analysis of randomized controlled trial. Int J Surg. 2017 Apr;40:97-108. doi: 10.1016/j.ijsu.2017.02.060. Epub 2017 Feb 24. Review.</citation>
    <PMID>28254422</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Naveed Siddiqui</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Arthroplasty</keyword>
  <keyword>Knee</keyword>
  <keyword>Hip</keyword>
  <keyword>Intrathecal Morphine</keyword>
  <keyword>Urinary retention</keyword>
  <keyword>Opioid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

